To include your compound in the COVID-19 Resource Center, submit it here.

Platform production

RBC play Rubius ramps up for clinical trials with $100M crossover round

Just nine months after closing a $120 million series B round, Rubius Therapeutics Inc. caught the eye of crossover investors who participated in a new $100 million round that will enable the company to further expand its clinical program.

Rubius closed the round on March

Read the full 459 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers